How to Pay for Transformative Cell and Gene Therapies

Malik Kaman co-wrote this blog post with Bernadette Bourjolly. 

After two decades of failures and setbacks, it’s an exciting time in the field of cell and gene therapies as we witness pioneering advances in a wide range of indications in areas including blood cancers, immunodeficiency and ophthalmology. While cell and gene therapies represent a potential paradigm shift for the treatment of cancer and rare genetic disorders, funding and reimbursement of these unconventional therapies pose major challenges. 


>
Read More

ESMO 2017: Examining New Models to Define, Measure and Pay for Value

Can true value-based pricing ever be a reality in Europe? If the answer is no, we may well be headed towards a price/access “crisis” as rising oncology costs continue to outstrip country healthcare budgets. If the answer is yes, it certainly seems like there’s still a long way to go.


>
Read More

A New Era of Biosimilars in Oncology: Four Themes From ESMO 2017

The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.

At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:


>
Read More

Biosimilars: How Stakeholder Influence Varies by Therapeutic Category

Tamal Taru co-wrote this blog post with Sandeep Sangwan. This post was originally published on ZS's pharmaceuticals blog, The Active Ingredient.

Biosimilars are at a nascent stage in the U.S. The market has seen just one biosimilar in oncology in supportive care (Zarxio), two in immunology (Inflectra and Renflexis) and one in diabetes (Basaglar). The immunology and diabetes spaces have been exposed to biosimilars for less than a year, and the oncology space has yet to see a biosimilar in therapeutic care. However, more biosimilars are nearing approval in these therapy areas, and some big products are expected to face biosimilar competition by 2018.


>
Read More

Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More